Drug Trial Radar · NCT04492956
Effects of Ecopipam or Placebo in Adults With Stuttering (Speak Freely)
Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
68
Actual
Start
Oct 22, 2020
Primary completion
Mar 7, 2022
Study completion Apr 4, 2022
Sponsor
- Lead sponsor
- Emalex Biosciences Inc.Industry
- Sponsor type
- Industry
- Collaborators
- University of California, Riverside; Premier Research
- First posted
- Jul 30, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase 2 exploratory study in adult subjects with childhood onset fluency disorder.
Conditions
- Childhood-Onset Fluency Disorder (Stuttering)
Interventions
EcopipamDrug
Oral tablet
PlaceboDrug
Oral tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Stuttering Severity Instrument, 4th Edition (SSI-4)Time frame: 12 weeks
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
UC Riverside
Riverside, California
CI Trials
Santa Ana, California
Clinical Neuroscience Solutions Inc
Jacksonville, Florida
Clinical Neuroscience Solutions Inc
Orlando, Florida
Institute For Advanced Medical Research
Atlanta, Georgia
Social Psychiatry Research Institute
Prairie Village, Kansas
Michigan State University
East Lansing, Michigan
Social Psychiatry Research Institute
Brooklyn, New York
Clinical Neuroscience Solutions Inc
Memphis, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.